The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing. Click to read.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

which according to Insmed is the drug in the DPP1 inhibitor class to be reviewed for the treatment of neutrophil-mediated diseases. Shares in Insmed have almost tripled over the past year on the ...

There were also signs that the M-AAT being produced was functional, as there was a decrease in the activity of neutrophil elastase, which causes lung damage in AATD and is inhibited by the wild ...

28 Aα-Val360 is a neutrophil elastase (NE) specific fibrinogen cleavage footprint measured by sandwich ELISA.29 Myeloperoxidase (MPO) and NE were measured using commercial kits (R&D Systems) according ...

Baseline serum IL-40 correlated with rheumatoid factor (IgM) (p<0.01), anti-cyclic citrullinated peptide (p<0.01) autoantibodies and NETosis markers (proteinase 3; neutrophil elastase (NE); ...

The involvement of enzymes such as neutrophil elastase (NE) and myeloperoxidase (MPO) in myocardial and liver fibrosis remains poorly understood. Future research should aim to clarify the specific ...